Overview

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2031-07-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

Phase:

PHASE3

Details

Lead Sponsor:

Hoffmann-La Roche

Collaborator:

Prothena Biosciences Limited